Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
NCT ID: NCT01077518
Last Updated: 2020-03-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
346 participants
INTERVENTIONAL
2010-08-26
2018-12-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
NCT01294579
First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years
NCT03492775
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
NCT01059630
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
NCT01456351
Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line
NCT01127841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Biologics have demonstrated enhanced efficacy when added to chemotherapeutic combinations in the frontline treatment for indolent NHL. The combination of ofatumumab and bendamustine may provide additional clinical benefit and efficacy to those who no longer respond to rituximab or rituximab-containing regimens.
The objective of this study is to determine the effect of ofatumumab and bendamustine combination therapy in patients with indolent B-cell NHL that did not respond to rituximab or a rituximab-containing regimen during or within 6 months of the last rituximab treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ofatumumab and Bendamustine (Arm A)
Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
Ofatumumab
Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
Ofatumumab and Bendamustine infusions (Arm A)
Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
Bendamustine (Arm B)
Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
Ofatumumab
Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
Bendamustine infusion
Bendamustine 100 mg/vial, injection
Bendamustine infusion (Arm B)
Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ofatumumab
Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
Bendamustine infusion
Bendamustine 100 mg/vial, injection
Ofatumumab and Bendamustine infusions (Arm A)
Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
Bendamustine infusion (Arm B)
Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimen
* Indolent lymphoma including grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage II (i.e. as any single mass \> 5 cm in any direction)
* ECOG Performance Status of 0, 1, or 2
* Life expectancy of at least 6 months
* 18 years or older
* Signed, written informed consent
Exclusion Criteria
* Previous allogeneic stem cell transplant
* Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 months
* Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two or to more than 3 vertebral bodies
* High dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within 3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the time of randomization
* Prior bendamustine treatment within 1 year of randomization not resulting in a CR or PR for at least 6 months
* Treatment with anti-CD20 monoclonal antibody within 3 months of randomization
* Known CNS involvement of indolent lymphoma
* Other past or current malignancy. Subjects free of malignancy for at least 5 years or have history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible
* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
* Clinically significant cardiac disease
* History of significant cerebrovascular disease or event with significant symptoms
* Positive serology for Hepatitis B
* Current active liver or biliary disease (except Gibber's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease)
* Known HIV positive
* Abnormal/inadequate blood values, liver and kidney function
* Current participation in other clinical study
* Inability to comply with the protocol activities
* Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Tucson, Arizona, United States
Novartis Investigative Site
Beverly Hills, California, United States
Novartis Investigative Site
Palm Springs, California, United States
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Coeur d'Alene, Idaho, United States
Novartis Investigative Site
Silver Spring, Maryland, United States
Novartis Investigative Site
Detroit, Michigan, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Mineola, New York, United States
Novartis Investigative Site
Rochester, New York, United States
Novartis Investigative Site
Danville, Pennsylvania, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Nashville, Tennessee, United States
Novartis Investigative Site
Richmond, Virginia, United States
Novartis Investigative Site
Seattle, Washington, United States
Novartis Investigative Site
Morgantown, West Virginia, United States
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Derqui, Pilar, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, , Argentina
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Innsbruck, , Austria
Novartis Investigative Site
Leoben, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Salzburg, , Austria
Novartis Investigative Site
Steyr, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Bruges, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Ghent, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Barrie, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada
Novartis Investigative Site
Avignon, , France
Novartis Investigative Site
Clermont-Ferrand, , France
Novartis Investigative Site
Grenoble, , France
Novartis Investigative Site
La Roche-sur-Yon, , France
Novartis Investigative Site
Le Mans, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Nantes, , France
Novartis Investigative Site
Nantes, , France
Novartis Investigative Site
Pessac, , France
Novartis Investigative Site
Saint-Denis, , France
Novartis Investigative Site
Saint-Pierre, , France
Novartis Investigative Site
Tours, , France
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Aschaffenburg, Bavaria, Germany
Novartis Investigative Site
Fürth, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Weilheim, Bavaria, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Giessen, Hesse, Germany
Novartis Investigative Site
Hanau, Hesse, Germany
Novartis Investigative Site
Kassel, Hesse, Germany
Novartis Investigative Site
Marburg, Hesse, Germany
Novartis Investigative Site
Bielefeld, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bottrop, North Rhine-Westphalia, Germany
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Goch, North Rhine-Westphalia, Germany
Novartis Investigative Site
Herford, North Rhine-Westphalia, Germany
Novartis Investigative Site
Leverkusen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Paderborn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Recklinghausen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Kaiserslautern, Rhineland-Palatinate, Germany
Novartis Investigative Site
Koblenz, Rhineland-Palatinate, Germany
Novartis Investigative Site
Neunkirchen, Saarland, Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Bremen, , Germany
Novartis Investigative Site
Alexandroupoli, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Haidari, Athens, , Greece
Novartis Investigative Site
Heraklion, Crete, , Greece
Novartis Investigative Site
Ioannina, , Greece
Novartis Investigative Site
Piraeus, , Greece
Novartis Investigative Site
Shatin, New Territories, , Hong Kong
Novartis Investigative Site
Tuenmen, , Hong Kong
Novartis Investigative Site
San Giovanni Rotondo, Apulia, Italy
Novartis Investigative Site
Reggio Calabria, Calabria, Italy
Novartis Investigative Site
Napoli, Campania, Italy
Novartis Investigative Site
Meldola (FC), Emilia-Romagna, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Genoa, Liguria, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Novara, Piedmont, Italy
Novartis Investigative Site
Terni, Umbria, Italy
Novartis Investigative Site
Verona, Veneto, Italy
Novartis Investigative Site
Aichi, , Japan
Novartis Investigative Site
Fukuoka, , Japan
Novartis Investigative Site
Hiroshima, , Japan
Novartis Investigative Site
Hyōgo, , Japan
Novartis Investigative Site
Ibaraki, , Japan
Novartis Investigative Site
Kanagawa, , Japan
Novartis Investigative Site
Miyagi, , Japan
Novartis Investigative Site
Okayama, , Japan
Novartis Investigative Site
Osaka, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Gdansk, , Poland
Novartis Investigative Site
Gdynia, , Poland
Novartis Investigative Site
Legnica, , Poland
Novartis Investigative Site
Opole, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Wroclaw, , Poland
Novartis Investigative Site
Wroclaw, , Poland
Novartis Investigative Site
Hato Rey, , Puerto Rico
Novartis Investigative Site
San Juan, , Puerto Rico
Novartis Investigative Site
Chelyabinsk, , Russia
Novartis Investigative Site
Kaluga, , Russia
Novartis Investigative Site
Kazan', , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Nizhny Novgorod, , Russia
Novartis Investigative Site
Novosibirsk, , Russia
Novartis Investigative Site
Penza, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
St'Petersburg, , Russia
Novartis Investigative Site
Tula, , Russia
Novartis Investigative Site
Ufa, , Russia
Novartis Investigative Site
Volgograd, , Russia
Novartis Investigative Site
Bratislava, , Slovakia
Novartis Investigative Site
Kyiv, , Ukraine
Novartis Investigative Site
Lviv, , Ukraine
Novartis Investigative Site
Makiivka, , Ukraine
Novartis Investigative Site
Plymouth, Devon, United Kingdom
Novartis Investigative Site
Northwood, Middlesex, United Kingdom
Novartis Investigative Site
Harrow, , United Kingdom
Novartis Investigative Site
Southampton, , United Kingdom
Novartis Investigative Site
Uxbridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rummel MJ, Janssens A, MacDonald D, Keating MM, Zaucha JM, Davis J, Lasher J, Babanrao Pisal C, Izquierdo M, Friedberg JW. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study). Br J Haematol. 2021 Jun;193(6):1123-1133. doi: 10.1111/bjh.17420. Epub 2021 May 10.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-004177-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
COMB157E2301
Identifier Type: OTHER
Identifier Source: secondary_id
110918
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.